Top 10 Selling Cancer Drugs of 2024

By Editorial Team
  1. Keytruda - $29.5 billion
  2. Darzalex - $9 billion
  3. Opdivo - $7 billion
  4. Imbruvica - $5billion
  5. Tagrisso - $5 billion
  6. Revlimid - $4 billion
  7. Verzenio - $4 billion
  8. Imfinzi - $4 billion
  9. Ibrance - $3 billion
  10. Tecentriq - $3 billion
In the rapidly evolving field of oncology, several cancer drugs have become best-sellers due to their proven effectiveness against various cancer types. Below, we examine some of the top-selling cancer drugs, highlighting their FDA-approved indications, mechanisms of action, and sales figures.

1. Keytruda (Pembrolizumab) - $29.5 billion

Indications Approved by FDA:
    • Non-small cell lung cancer (NSCLC)
    • Melanoma
    • Head and neck squamous cell carcinoma (HNSCC)
    • Classical Hodgkin lymphoma
    • Urothelial carcinoma
    • Gastric cancer
    • Esophageal cancer
    • Triple-negative breast cancer (TNBC)
    • Renal cell carcinoma (RCC)
    • Microsatellite instability-high (MSI-H) cancers
    • Colorectal cancer
    • Hepatocellular carcinoma (HCC)
    • Cervical cancer
Mechanism of Action: Keytruda is a monoclonal antibody that targets the programmed death-1 (PD-1) receptor on T cells. By binding to PD-1, it prevents the interaction between PD-1 and its ligands, PD-L1 and PD-L2, which are often overexpressed on cancer cells. This blockade reactivates T cells, allowing them to recognize and attack cancer cells.

Company: Merck & Co.
2023 sales: $25 billion
2024 sales: $29.5 billion

In 2024, Keytruda’s sales grew 18% at constant exchange rates, reaching $29.5 billion. After AbbVie's Humira lost U.S. market exclusivity and as demand for COVID vaccines plummeted at the end of the pandemic, Merck & Co.’s Keytruda was finally able to claim the title of the world’s bestselling medicine in 2023. 

2. Darzalex (Daratumumab) - $11.6 billion

Indication Approved by FDA: Multiple myeloma and light chain amyloidosis.

Mechanism of Action: Darzalex is a monoclonal antibody that targets CD38, a glycoprotein expressed on the surface of multiple myeloma cells. By binding to CD38, Darzalex induces tumor cell death through multiple mechanisms, including complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and antibody-dependent cellular phagocytosis. It also modulates the immune system to attack the cancer cells.

Company: Johnson & Johnson
2023 sales: $9.7 billion
2024 sales: $11.6 billion

The Darzalex franchise, including the subcutaneous formulation Darzalex Faspro, was Johnson & Johnson’s second-largest brand last year. With $9.74 billion in global sales, the multiple myeloma drug accounted for 11.4% of the pharma and medtech giant’s total revenue haul for the year. 

Darzalex secured its initial FDA approval in 2015 as a fourth-line multiple myeloma treatment and the first monoclonal antibody for the blood cancer. It entered the first-line setting in 2018 as part of a now outdated combination including Takeda’s Velcade, the alkylating agent melphalan and the corticosteroid prednisone.   

Much more recently, the J&J drug has shown promise as part of an advanced combo with Velcade, Bristol Myers Squibb’s Revlimid and the steroid dexamethasone (VRd). Late last year, the Darzalex-containing four-drug regimen showed it could slash the risk of progression or death by 58% versus VRd alone in first-line myeloma patients who’re eligible for stem cell transplants. The company filed that combo with the FDA in January and secured a priority review. 

3. Opdivo (Nivolumab) - $7 billion

Indications Approved by FDA:
  • NSCLC
  • Melanoma
  • RCC
  • HNSCC
  • Urothelial carcinoma
  • Classical Hodgkin lymphoma
  • Hepatocellular carcinoma
  • Esophageal squamous cell carcinoma
  • Gastric cancer
  • Colorectal cancer with MSI-H/dMMR
  • Small cell lung cancer (SCLC)
Mechanism of Action: Opdivo is another immune checkpoint inhibitor that targets the PD-1 receptor on T cells. Like Keytruda, it blocks the PD-1/PD-L1 interaction, enhancing the immune system's ability to recognize and destroy cancer cells.

Companies: Bristol Myers Squibb and Ono Pharmaceutical
2023 sales: $10 billion
2024 sales: $9.3 billion

Bristol Myers Squibb (BMY) and Ono Pharmaceutical’s Opdivo, a treatment for melanoma and other cancers, generated $9.3 billion in global sales. In 2024, the melanoma-fighting medication alone accounted for nearly 20% of the company’s $48.3 billion in annual revenue.

Opdivo generated $10 billion in global sales last year, with $9 billion going to Bristol Myers Squibb and 148 billion Japanese yen ($1 billion) going to Ono Pharmaceutical.

4. Tagrisso (Osimertinib) - $5 billion

Indications Approved by FDA: 
  • EGFR T790M mutation-positive NSCLC
  • First-line treatment of metastatic NSCLC with EGFR exon 19 deletions or exon 21 L858R mutations
Mechanism of Action: Tagrisso is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). It selectively inhibits both EGFR sensitizing mutations and the T790M resistance mutation, which is a common cause of resistance to earlier-generation EGFR TKIs. By blocking these mutations, Tagrisso inhibits cancer cell proliferation and induces apoptosis.

5. Revlimid (Lenalidomide) - $5 billion

Indications Approved by FDA:
  • Multiple myeloma
  • Mantle cell lymphoma
  • Myelodysplastic syndromes (MDS)
  • Follicular lymphoma
Mechanism of Action: Revlimid is an immunomodulatory drug that has multiple mechanisms of action, including direct anti-proliferative effects on tumor cells, inhibition of angiogenesis, and immune system modulation. It also enhances T-cell and natural killer (NK) cell-mediated cytotoxicity and reduces the production of pro-inflammatory cytokines.

6. Verzenio (Abemaciclib) - $4 billion

Indications Approved by FDA: HR-positive, HER2-negative advanced or metastatic breast cancer

Mechanism of Action: Verzenio is an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6). By inhibiting CDK4/6, Verzenio prevents the phosphorylation of the retinoblastoma protein (Rb), leading to cell cycle arrest at the G1 phase, thereby inhibiting the proliferation of cancer cells.

7. Imfinzi (Durvalumab) - $4 billion

Indications Approved by FDA:
  • Unresectable stage III NSCLC
  • Extensive-stage small cell lung cancer (ES-SCLC)
  • Urothelial carcinoma
Mechanism of Action: Imfinzi is a monoclonal antibody that targets PD-L1, a ligand for PD-1. By binding to PD-L1, Imfinzi prevents it from interacting with PD-1 on T cells, thereby restoring immune responses and allowing the immune system to attack the cancer.

8. Ibrance (Palbociclib) - $4 billion

Indications Approved by FDA: HR-positive, HER2-negative advanced or metastatic breast cancer

Mechanism of Action: Ibrance is an oral CDK4/6 inhibitor, similar to Verzenio. It works by inhibiting CDK4/6, which leads to cell cycle arrest in the G1 phase. This action reduces cancer cell proliferation, particularly in HR-positive breast cancer.

9. Perjeta (Pertuzumab) - $3 billion

Indications Approved by FDA: HER2-positive breast cancer

Mechanism of Action: Perjeta is a monoclonal antibody that targets the HER2 receptor, a protein that is overexpressed in some breast cancers. Perjeta binds to a different epitope on HER2 than Herceptin (trastuzumab), allowing for a more comprehensive blockade of HER2 signaling. This dual inhibition results in a more potent suppression of tumor growth.

10. Tecentriq (Atezolizumab) - $3 billion

Indications Approved by FDA:
  • NSCLC
  • SCLC
  • Urothelial carcinoma
  • Triple-negative breast cancer (TNBC)
  • Hepatocellular carcinoma (HCC)
Mechanism of Action: Tecentriq is a monoclonal antibody that targets PD-L1, similar to Imfinzi. By blocking the PD-L1/PD-1 interaction, Tecentriq reactivates T cells to detect and destroy cancer cells.


Sources:

Summit Therapeutics falls after mixed data from late-stage study of Ivonescimab plus chemotherapy cancer trial: Update (May 2025)


Comments

Post a Comment

Popular posts from this blog

Ivermectin for Cancer Treatment: Protocols and Evidence (2025 Edition)

By Editorial Team
Image
Ivermectin, a drug primarily used to treat parasitic infections, has gained attention for its potential anti-cancer properties, particularly in alternative treatment protocols. Popularized by figures like Dr. William Makis, these protocols combine ivermectin with supplements and lifestyle changes to target aggressive cancers. This article explores the science, protocols, case reports, risks, and controversies surrounding ivermectin’s use in cancer treatment, providing a balanced guide for readers. What is the Ivermectin Cancer Protocol? Ivermectin cancer protocols, notably those developed by Dr. William Makis, combine ivermectin with supplements like curcumin, vitamin D, and berberine, alongside dietary and lifestyle changes. These protocols are tailored to cancer severity, with higher doses recommended for aggressive cases. The term “turbo cancers,” used by some proponents, refers to rapidly progressing cancers, though it is not a standard medical term and lacks clear scientific defin...
Read more

Fenbendazole vs Ivermectin for Cancer: Differences and Which Is Better?

By Editorial Team
Image
Cancer patients are increasingly inquiring about the use of the anthelmintic drugs Fenbendazole (FenBen) and Ivermectin (IVM) as potential treatments for cancer. Notably, these patients typically fall into two distinct groups, neither of which represents the usual stage 1 or 2 cancer cases where conventional therapies often show promise. The first group consists of older men whose lung or prostate cancer has recurred. Having undergone conventional treatments previously without success, they express skepticism about its effectiveness this time around. The second, larger group comprises younger patients under 40 dealing with aggressive breast cancer, colorectal cancer, or lymphoma—forms of early-onset cancers that appear to lack the typical mutations observed in traditional cases. This article aims to delve into the differences between Fenbendazole and Ivermectin by examining their me...
Read more

Exploring Ivermectin, Mebendazole and Fenbendazole as Aggressive Cancer Treatments: Research, Protocols, and Controversies (2025)

By Editorial Team
Image
Fenbendazole and ivermectin, both antiparasitic drugs that have shown potential in cancer treatment through several mechanisms, such as slowing cancer cell growth and boosting the immune response. Fenbendazole is being studied for its ability to disrupt energy production in cancer cells, effectively hindering their growth. Ivermectin, on the other hand, has been explored in combination with checkpoint inhibitors to boost the immune system's response to tumors—especially in challenging cases like triple-negative breast cancer. Introduction Cancer remains a leading cause of morbidity and mortality worldwide, with an increasing incidence of aggressive and treatment-resistant tumors such as triple-negative breast cancer (TNBC), pancreatic adenocarcinoma, and glioblastoma. Despite significant advances in targeted therapies and immunotherapies, many patients continue to face limited effective options, highlighting an urgent need for novel, affordable, and accessible treatment strategies....
Read more

Top 10 Cancer Fighting Supplements: Evidence Based Literature Review (2025)

By Editorial Team
Image
Are you overwhelmed by conflicting advice on cancer, diet, and supplements ? You’re not alone. With so many claims out there, it’s hard to separate fact from fiction . Can certain foods lower your cancer risk ? Are some foods increasing it without you realizing? What about vitamin and mineral supplements —do they help prevent cancer, or could they actually increase your risk ? The term " anti-cancer supplements " can be misleading. While some nutrients support the body in cancer prevention or treatment, others may interfere with therapies or even pose risks. This guide compiles over 500 scientific references on cancer, diet, and supplements—helping you navigate the facts with ...
Read more

Fenbendazole and Ivermectin for Cancer Case Series: Over 160 Case Reports (2025)

By Editorial Team
Image
Anecdotal reports and preliminary studies suggest that ivermectin and fenbendazole, both antiparasitic drugs, may have potential anticancer effects when used alongside other treatments.  Many people immediately dismiss the potential of ivermectin and fenbendazole when they learn it is “horse or dog medicine”. That initial reaction is overcome when genuine human success stories are told including the lack of serious side effects. The testimonials you are about to read are from individuals who have bravely shared their experiences in the hope of inspiring and uplifting others. These are raw human accounts, unfiltered by gatekeepers—not peer-reviewed studies—but they offer insights that may be valuable to those searching for options. However, we acknowledge that robust clinical trials are needed to provide more conclusive scientific evidence. Contents: Editor's Preface Introduction Fenbendazole and Ivermectin Case Series Compilation (alphabetical) Breast Cancer Success Stories  (...
Read more

Fenbendazole and the Joe Tippens Cancer Protocol: A Comprehensive Guide (2025)

By Editorial Team
Image
The Joe Tippens Cancer Protocol has gained attention as an alternative approach to cancer treatment, popularized by Joe Tippens, a cancer survivor who credits his recovery to fenbendazole, a veterinary anthelmintic, combined with supplements. This article provides a step-by-step guide to the protocol, explores its scientific basis, shares case reports, and discusses risks and controversies to help readers make informed decisions. What is the Joe Tippens Protocol? The Joe Tippens Protocol involves fenbendazole, a drug typically used to treat parasitic infections in animals, alongside supplements and lifestyle changes. The protocol aims to disrupt cancer cell growth, though it remains experimental and lacks approval for human use by regulatory bodies like the FDA. Below is a summary of the protocol’s components, as updated in 2020: Lifestyle Recommendations : Diet : Eliminate refined sugars and processed foods; focus on whole foods like vegetables, lean proteins, and healthy fats. Exerci...
Read more

Fenbendazole Dosage for Cancer in Humans: Benefits, Risks, and Guidelines (2025)

By Editorial Team
Image
What is Fenbendazole? Fenbendazole is an anthelmintic drug commonly used to treat parasitic infections in animals. However, recent research and anecdotal reports suggest it may have potential anticancer properties in humans. How Does Fenbendazole Work for Cancer? Fenbendazole is believed to work by disrupting microtubules in cancer cells, leading to cell cycle arrest and apoptosis (cell death). Some studies suggest it may also modulate glucose metabolism, limiting cancer cell energy supply. Recommended Fenbendazole Dosage for Cancer in Humans The commonly referenced Joe Tippens Protocol suggests the following dosage: Potential Side Effects of Fenbendazole in Humans While generally considered safe, potential side effects may include: Gastrointestinal discomfort (nausea, diarrhea, bloating) Liver enzyme elevation (rare) Bone marrow suppression (rare) Safety and Precautions Medical Supervision: Always consult with a doctor, especially if combining with other treatments. Drug Interaction...
Read more

Fact Check: Can Ivermectin and Fenbendazole Help Treat Cancer?

By Editorial Team
Image
Ivermectin and fenbendazole, originally developed as antiparasitic drugs, are sparking hope in the fight against cancer, fueled by inspiring stories like those shared by actor  Mel Gibson on The Joe Rogan Experience , where he celebrated friends’ remarkable recoveries. While these medications aren’t yet standard cancer treatments, early research is uncovering exciting potential. Scientists are encouraged by promising lab studies and are calling for more clinical trials to confirm their effectiveness and ensure safe use in humans, paving the way for innovative, accessible therapies that could transform lives. Introduction and Context According to a January 22, 2025 fact-check article by AFP: "The anti-parasitic drugs ivermectin and fenbendazole are not currently recommended for cancer, but posts spread across social media touting the medications after actor  Mel Gibson claimed on the Joe Rogan Experience  that they cured his friends' cases of the disease. Oncology ex...
Read more

How One Cancer Survivor Triggered Interest in Repurposed Anti-Parasitic Drugs

By Editorial Team
Image
Joe Tippens never planned to discover a potential remedy that he credits with saving his life and thrust him into the spotlight among notable cancer survivors. The 67-year-old businessman told The Epoch Times he just wanted to beat a type of cancer with an extremely low survival rate. In August 2016, Tippens was diagnosed with small cell lung cancer with a fist-sized tumor. After undergoing chemotherapy and radiation five times a week in Houston, the large tumor in his left lung was eliminated. However, Tippens said the treatments came closer to killing him than curing him. When he returned home to Oklahoma after the New Year, he received devastating news. His oncologist told him he had zero chance of surviving for more than a few months. “In January of 2017, my PET scan lit up like a Christmas tree and I had wide metastasis everywhere, including in my neck, bones, pancreas, and liver,” Tippens said. Finding a Lifeline Facing a prognosis of three months to live, Tippens heard an intrig...
Read more

2025 Study: Ivermectin and Balstilimab for Stage 4 Triple Negative Breast Cancer - Cedars-Sinai Medical Center Study

By Editorial Team
Image
Authors: Yuan Yuan, Jin Sun Bitar, MaLia Walker, David Lin, January Lee, So Yung Choi, Stephen Shiao, Mourad Tighiouart, Paul H. Frankel, Peter P. Lee Affiliation: Cedars-Sinai Medical Center, Los Angeles, CA Abstract e13146  (2025 ASCO Annual Meeting) is a phase 1/2 study of ivermectin in combination with balstilimab after 1-2 prior lines of therapy for triple negative breast cancer Background: Despite recent FDA approval of immune checkpoint inhibitor (ICI) and antibody-drug conjugates (ADCs), therapeutic options for metastatic triple negative breast cancer (mTNBC) remain limited. Preclinical data showed that ivermectin induces robust T cell infiltration into breast tumors and turning “cold” tumors “hot” in mouse model of TNBC. Balstilimab is a fully humanized IgG4 anti-PD-1 agent with proven safety and efficacy in metastatic cervical cancer. The current phase I/II trial is designed to test the safety and efficacy of the combination of ivermectin and balstilimab in patients wit...
Read more